XML 94 R64.htm IDEA: XBRL DOCUMENT v3.22.4
Discontinued Operations - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Jul. 06, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Gain (loss) on sale of business   $ 0.0 $ 47.5 $ (20.9)
Foreign currency translation gain $ 159.3      
RX Pharmaceuticals | Discontinued Operations, Disposed of by Sale        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Total consideration in definitive agreement to sell 1,550.0      
Potential R&D milestone payments and contingent purchase obligations assumed by purchaser 53.3      
Gain (loss) on sale of business $ 47.5      
Separation costs     $ 40.8  
Supply agreement term 4 years      
Supply agreement, extension period 7 years      
Aggregate cap on buyer's obligation for certain pre-closing liabilities (percent) 50.00%      
Aggregate cap on buyer's obligation for certain pre-closing liabilities $ 50.0